Evidence map›Paper›PMID 32735606›Full record

ArticlePloS one2020

Structure-guided screening strategy combining surface plasmon resonance with nuclear magnetic resonance for identification of small-molecule Argonaute 2 inhibitors.

Toshimasa Harumoto, Atsuko Sato, Yuki Takayama, Hikaru Miyagi, Jun-Ichi Saito, Fumikazu Shinohara

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Toshimasa HarumotoResearch Functions Unit, R&D Division, Kyowa Kirin Co., Ltd., Machida-shi, Tokyo, Japan.ORCID 0000-0003-0669-8721
Atsuko SatoResearch Functions Unit, R&D Division, Kyowa Kirin Co., Ltd., Nagaizumi-cho, Suntou-gun, Shizuoka, Japan.
Yuki TakayamaResearch Functions Unit, R&D Division, Kyowa Kirin Co., Ltd., Nagaizumi-cho, Suntou-gun, Shizuoka, Japan.
Hikaru MiyagiResearch Functions Unit, R&D Division, Kyowa Kirin Co., Ltd., Machida-shi, Tokyo, Japan.
Jun-Ichi SaitoResearch Functions Unit, R&D Division, Kyowa Kirin Co., Ltd., Nagaizumi-cho, Suntou-gun, Shizuoka, Japan.
Fumikazu ShinoharaResearch Functions Unit, R&D Division, Kyowa Kirin Co., Ltd., Otemachi, Chiyoda-ku, Tokyo, Japan.
Kyowa Kirin (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Argonaute (AGO) proteins are the key component of the RNA interference machinery that suppresses gene expression by forming an RNA-induced silencing complex (RISC) with microRNAs (miRNAs). Each miRNA is involved in various cellular processes, such as development, differentiation, tumorigenesis, and viral infection. Thus, molecules that regulate miRNA function are expected to have therapeutic potential. In addition, the biogenesis of miRNA is a multistep process involving various proteins, although the complete pathway remains to be elucidated. Therefore, identification of molecules that can specifically modulate each step will help understand the mechanism of gene suppression. To date, several AGO2 inhibitors have been identified. However, these molecules were identified through a single screening method, and no studies have specifically evaluated a combinatorial strategy. Here, we demonstrated a combinatorial screening (SCR) approach comprising an in silico molecular docking study, surface plasmon resonance (SPR) analysis, and nuclear magnetic resonance (NMR) analysis, focusing on the strong binding between the 5'-terminal phosphate of RNA and the AGO2 middle (MID) domain. By combining SPR and NMR, we identified binding modes of amino acid residues binding to AGO2. First, using a large chemical library (over 6,000,000 compounds), 171 compounds with acidic functional groups were screened using in silico SCR. Next, we constructed an SPR inhibition system that could analyze only the 5'-terminal binding site of RNA, and nine molecules that strongly bound to the AGO2 MID domain were selected. Finally, using NMR, three molecules that bound to the desired site were identified. The RISC inhibitory ability of the "hit" compounds was analyzed in human cell lysate, and all three hit compounds strongly inhibited the binding between double-stranded RNA and AGO2.

Indexed as

Magnetic Resonance SpectroscopySurface Plasmon ResonanceArgonaute ProteinsComputer SimulationDrug Evaluation, PreclinicalHeLa CellsHumansMolecular Docking SimulationProtein ConformationSmall Molecule LibrariesAGO2 protein, humanArgonaute ProteinsSmall Molecule Libraries

Identifiers

PMID32735606
PMCPMC7394379
OpenAlexW3046873012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.